A second, experimental Covid-19 vaccine developed by the UK researchers is starting its human testing in humans this week. Developed with the cutting-edge technology, the scientists hope that the success of this vaccine will allow the manufacture of hundreds of doses of the vaccine to be produced quickly.
The vaccine developed by the scientists from the Imperial College London is supported by 41 million pounds in the UK funding along with accessory round of 5 million pounds of donations. The same further includes contribution from the public too.
Robin Shattock, the lead author of the study, called this vaccine one based off of technology called the self-amplifying RNA. If the first round of the clinical trials produces promising results, further larger trials would be put in place consisting of over 6,000 participants.
The University of Oxford is currently working with AstraZeneca Plc, Moderna Inc. and CanSino Biologics Inc. to further develop a working Covid-19 vaccine. They are currently undergoing clinical trials as the government is working to flatten the curve.
The RNA vaccine developed by Imperial College London works by injecting the genetic code into the muscle directly. This then instructs to develop a protein on the surface of the virus, triggering a protective immune response.
The British University also stated in a statement earlier that they were setting up ways to further distribute all the vaccines at a lower price. Alongside Morningside Ventures, Imperial is going to waive off the extreme royalties and only charge the modest cost to help sustain the work of the organisation.
